Main Article Content


Introduction: Neuropathic pain is challenging to manage in children compounded by inappropriate assessment tools.  The lack of evidence-based pain control guidelines for children results in clinicians deferring to expert opinion and personal preference. Children with Guillain-Barré Syndrome are particularly at risk is of neuropathic pain.
Objectives and Methods: This is a retrospective study of children with Guillain-Barré Syndrome who were admitted to Red Cross War Memorial Children’s Hospital, Cape Town, South Africa over a 10 year period. The study reviewed their pain assessment and management practice.
Results: Eighty-four children were identified with Guillain-Barré Syndrome.  76% had symptoms of pain and 53% had breakthrough pain reported.  Standardised pain rating scales were used in 3 patients.  A mean of 2.7 analgesics were used per patient. Carbamazepine and gabapentin, were utilised in 27 and 20 patients respectively.  The use of gabapentin increased 73% per annum from 2009.  There was no statistical difference between these two groups for length of hospital stay or long-term disability.
Conclusion: This study identified a significant gap in the assessment of pain in children with Guillain-Barré Syndrome.  Tools to adequately assess pain are needed, especially in immobile and non-verbal children.  Management of pain revealed a high use of adjuvant drugs. The dramatic increase in the use of gabapentin related to clinician preference and was not supported by any evidence.  Clinical outcomes for both the carbamazepine and the gabapentin group were no different.


Pain assessment tools gabapentin carbamazepine children acute inflammatory demyelinating polyradiculoneuropathy Guillain-Barré syndrome

Article Details

Author Biographies

Hayley Hutton, University of Cape Town

Paediatric Fellow, Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, University of Cape Town, South Africa

Jo Wilmshurst, University of Cape Town

Head of Paediatric Neurology, Neurosciences Insititute, Red Cross War Memorial Children's Hospital, University of Cape Town, South Africa

How to Cite
Hutton, H., & Wilmshurst, J. (2019). The assessment and management of pain in children with Guillain-Barré Syndrome in a sub-Saharan setting. Journal of the International Child Neurology Association, 1(1).


  1. Groenewald CB, Rabbitts JA, Schroeder DR, Harrison TE. Prevalence of moderate-severe pain in hospitalized children.. Paediatric anaesthesia.. 2012; 22(7):661-8.
  2. Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice.. The Journal of the American Board of Family Practice / American Board of Family Practice.. 2001; 14(3):211-8.
  3. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population.. BMC family practice.. 2013; 14:14-28.
  4. Gustavsson A, Bjorkman J, Ljungcrantz C, et al. Pharmacological treatment patterns in neuropathic pain--lessons from Swedish administrative registries.. Pain medicine (Malden Mass).. 2013; 14(7):1072-80.
  5. Friedrichsdorf SJ, Postier AC, Andrews GS, Hamre KE, Steele R, Siden H. Pain reporting and analgesia management in 270 children with a progressive neurologic metabolic or chromosomally based condition with impairment of the central nervous system: cross-sectional baseline results from an observational longitudinal study.. J Pain Res.. 2017; 10:1841-52.
  6. Madadi P, Enato EF, Fulga S. Patterns of paediatric analgesic use in Africa: a systematic review.. Archives of Disease in Childhood.. 2012; 97(12):1086-91.
  7. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes.. Neurology.. 2008; 70(18):1630-5.
  8. Walco GA, Dworkin RH, Krane EJ, LeBel AA, Treede RD. Neuropathic pain in children: Special considerations.. Mayo Clinic proceedings.. 2010; 85(3 Suppl):S33-41.
  9. Howard RF, Wiener S, Walker SM. Neuropathic pain in children.. Archives of Disease in Childhood.. 2014; 99(1):84-9.
  10. Brown S, Johnston B, Amaria K, et al. A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children.. Scand J Pain.. 2016; 13:156-63.
  11. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome.. Annals of Neurology.. 1990; 27 Suppl:S21-4.
  12. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study.. Archives of Disease in Childhood.. 1996; 74(4):281-7.
  13. Barzegar M, Dastgiri S, Karegarmaher MH, Varshochiani A. Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran.. BMC neurology.. 2007; 7:22.
  14. Sarkar UK, Menon L, Sarbapalli D, et al. Spectrum of Guillain-Barre syndrome in tertiary care hospital at Kolkata.. Journal of natural science biology and medicine.. 2011; 2(2):211-5.
  15. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barre syndrome.. Neurology.. 1997; 48(2):328-31.
  16. American Academy of Pediatrics Committee on Psychosocial Aspects of C Family H Task Force on Pain in Infants C and Adolescents. The assessment and management of acute pain in infants children and adolescents.. Pediatrics.. 2001; 108(3):793-7.
  17. Koch K. Paediatric pain management in general practice.. S Afrr Fam Pract.. 2012; 54:292-5.
  18. Chetty S, Baalbergen E, Bhigjee AI, et al. Clinical practice guidelines for management of neuropathic pain: expert panel recommendations for South Africa.. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 2012; 102(5):312-25.
  19. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society.. Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur.. 2014; 19(6):328-35.
  20. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. The Cochrane database of systematic reviews.. 2012; 7:CD008943.
  21. Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain.. Drugs.. 2007; 67(9):1265-89.
  22. Stewart K. Adjuvant medicines for the management of neuropathic pain.. Nursing standard (Royal College of Nursing (Great Britain) : 1987).. 2010; 25(7):35-8.
  23. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.. The Cochrane database of systematic reviews.. 2013; 11(11):CD010567.
  24. Peña L, Moreno CB, Gutierrez-Alvarez AM. Pain management in Guillain-Barre syndrome: a systematic review.. Neurologia.. 2015; 30(7):433-8.
  25. Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome.. Cochrane Database Syst Rev.. 2015; 9(4):CD009950.
  26. Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in guillain-barre syndrome: a double-blinded placebo-controlled crossover study.. Anesthesia and Analgesia.. 2002; 95(6):1719-23.
  27. Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit.. Anesthesia and Analgesia.. 2005; 101(1):220-5.
  28. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults.. The Cochrane database of systematic reviews.. 2011; 1(1):CD005451.
  29. McDouall SF, Tasker RC. Are anticonvulsants a satisfactory alternative to opiate analgesia in patients experiencing pain with Guillain-Barre syndrome?. Archives of Disease in Childhood.. 2004; 89(7):686-7.
  30. van der Pijl J, Wilmshurst JM, van Dijk M, Argent A, Booth J, Zampoli M. Acute flaccid paralysis in South African children: Causes respiratory complications and neurological outcome.. J Paediatr Child Health.. 2018; 54(3):247-53.
  31. von Baeyer CL, Spagrud LJ. Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years.. Pain.. 2007; 127(1-2):140-50.
  32. McGrath PJ, Walco GA, Turk DC, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations.. The journal of pain : official journal of the American Pain Society.. 2008; 9(9):771-83.
  33. Cooper TE, Wiffen PJ, Heathcote LC, et al. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.. Cochrane Database Syst Rev.. 2017; 8:CD012536.
  34. Massaro M, Ronfani L, Ferrara G, et al. A comparison of three scales for measuring pain in children with cognitive impairment.. Acta Paediatrica (Oslo Norway : 1992).. 2014; 103(11):e495-500.
  35. Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barre syndrome.. The Cochrane database of systematic reviews.. 2013; 10:CD009950.
  36. Irving GA. Contemporary assessment and management of neuropathic pain.. Neurology.. 2005; 64(12 Suppl 3):S21-7.
  37. Samia P, Petersen R, Walker KG, Eley B, Wilmshurst JM. Prevalence of seizures in children infected with human immunodeficiency virus.. Journal of child neurology.. 2013; 28(3):297-302.
  38. Irving G. Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians.. Therapeutic advances in chronic disease.. 2012; 3(5):211-8.
  39. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.. The Clinical journal of pain.. 2001; 17(4):284-95.

Most read articles by the same author(s)